[Form 4] Vera Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vera Therapeutics (VERA) filed a Form 4 showing director Patrick G. Enright, through Longitude Prime Fund and Longitude Venture Partners IV, bought 250,000 Class A shares on 23–24 Jun 2025 at weighted-average prices of $20.87–$22.35, spending roughly $5.3 million. Post-transaction indirect holdings rise to 5,394,212 shares, an increase of about 4.9%. All trades were open-market purchases (code 'P'); no sales or derivatives were reported. Footnotes disclose price ranges and standard Section 16 disclaimers. The scale and direction of the trade suggest insider confidence, but the filing offers no strategic commentary.

Positive

• $5.3 million insider purchase (250,000 shares) at ~$21.11 average, materially increasing indirect holdings to 5.39 million shares

Negative

• None.

Insights

Insider Trading Analyst

TL;DR: $5.3 M fund-level insider buy, no sales—bullish signal on valuation and outlook.

The coordinated purchase of 250,000 shares across two Longitude funds adds roughly 4.9% to their position, lifting indirect ownership to 5.39 million shares. Dollar value surpasses $5 million, well above routine thresholds and implying high conviction near recent price highs. Absence of 10b5-1 plan or derivative hedges points to discretionary buying. Such scale from a board member often precedes positive catalysts and tightens float, potentially supporting near-term share performance. Investors should, however, monitor future filings for additional accumulation or any switch to distribution mode.

Portfolio Risk Analyst

TL;DR: Positive sentiment, but indirect fund ownership tempers alignment; exit risk remains.

Although sizeable, the purchase was executed through venture funds, not personal accounts, limiting direct governance alignment and introducing eventual liquidity overhang when funds exit. Weighted-average prices indicate opportunistic accumulation rather than urgency, implying moderate—not emphatic—bullishness. Without complementary operational news, the transaction alone is unlikely to reshape long-term fundamentals, but it does modestly improve near-term sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENRIGHT PATRICK G

(Last) (First) (Middle)

C/O LONGITUDE CAPITAL MANAGEMENT

2740 SAND HILL ROAD, 2ND FLOOR

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/23/2025		P		69,798	A	$20.8683(1)	1,784,083	I	See footnote(2)
Class A Common Stock	06/23/2025		P		139,595	A	$20.8683(1)	3,569,522	I	See footnote(3)
Class A Common Stock	06/24/2025		P		13,536	A	$22.3517(4)	1,797,619	I	See footnote(2)
Class A Common Stock	06/24/2025		P		27,071	A	$22.3517(4)	3,596,593	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

2. These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

3. These shares are held by Longitude Venture Partners IV, L.P ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

4. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.

	/s/ Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Vera Therapeutics shares did Patrick Enright buy in June 2025?

The Form 4 reports purchases of 250,000 Class A shares on 23–24 June 2025.

What was the total dollar value of Enright’s insider purchase of VERA stock?

Based on weighted-average prices, the aggregate cost was approximately $5.3 million.

At what prices were the VERA shares purchased?

Shares were bought at weighted-average prices of $20.8683 on 23 Jun and $22.3517 on 24 Jun 2025.

What is Enright’s total beneficial ownership in VERA after these transactions?

Indirect holdings through Longitude funds increased to 5,394,212 Class A shares.

Did the Form 4 disclose any sales of VERA stock?

No. All four transactions were coded ‘P’ for open-market purchases; no sales or derivatives were reported.